收藏切换
The challenges of economic evaluation of drugs for rare diseases and thoughts of its countermeasures in China
收藏切换
Jiahao HU, Qi KANG, Lin ZHU, Yuhan LIU, Xiaohui HOU, Jiangjiang HE, Chunlin JIN*
World Clinical Drug | 2022, 43(2) : 109 - 114
Less
收藏切换
World Clinical Drug | 2022, 43(2): 109-114
• Topic •
The challenges of economic evaluation of drugs for rare diseases and thoughts of its countermeasures in China
Full
Jiahao HU, Qi KANG, Lin ZHU, Yuhan LIU, Xiaohui HOU, Jiangjiang HE, Chunlin JIN*
Affiliations
  • Shanghai Health Development Research Center, Shanghai 200040, China
Published: 2022-02-10 doi: 10.13683/j.wph.2022.02.001
Outline
收藏切换

With the release of the list of rare disease in China, the economic evaluation of drug use for rare disease is also gradually advancing. Rare disease is characterized by insufficient cognition and basic research, difficult diagnosis, difficult evaluation of therapeutic effect and difficult patients recruitments. Clinical studies on the use of rare diseases also have problems such as non-random design and short follow-up period, which increase the difficulty of pharmacoeconomic evaluation. In pharmacoeconomic evaluation of drugs for rare disease, problems may occur, such as difficulty in selecting reference drugs, uncertainty in model structure, difficulty and high uncertainty in obtaining efficacy data, safety data, cost and health utility parameters. Based on the above problems and challenges, this paper put forward countermeasures that could be taken by all stakeholders in China, so as to make a more objective and reasonable economic evaluation of drug use for rare disease, and reduced the uncertainty of results and decision-making uncertainty of medical insurance departments.

rare disease  /  drugs for rare disease  /  economic evaluation
胡嘉浩, 康琦, 朱琳, 刘宇晗, 侯晓慧, 何江江, 金春林. 罕见病用药经济学评价的挑战与中国对策思考. 世界临床药物, 2022 , 43 (2) : 109 -114 . DOI: 10.13683/j.wph.2022.02.001
Jiahao HU, Qi KANG, Lin ZHU, Yuhan LIU, Xiaohui HOU, Jiangjiang HE, Chunlin JIN. The challenges of economic evaluation of drugs for rare diseases and thoughts of its countermeasures in China[J]. World Clinical Drug, 2022 , 43 (2) : 109 -114 . DOI: 10.13683/j.wph.2022.02.001
Year 2022 volume 43 Issue 2
16
6
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.02.001
  • Receive Date:2021-12-29
  • Online Date:2026-11-19
  • Published:2022-02-10
Article Data
Affiliations
History
  • Received:2021-12-29
Funding
Affiliations
    Shanghai Health Development Research Center, Shanghai 200040, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.02.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT